LEADER 05352nam 22006374a 450 001 9910830009303321 005 20230617041819.0 010 $a9786610101603 010 $a0-470-86947-X 010 $a1-280-10160-1 010 $a0-470-86946-1 010 $a0-470-34553-5 035 $a(CKB)1000000000377325 035 $a(EBL)164848 035 $a(SSID)ssj0000230266 035 $a(PQKBManifestationID)11204200 035 $a(PQKBTitleCode)TC0000230266 035 $a(PQKBWorkID)10178691 035 $a(PQKB)11180801 035 $a(MiAaPQ)EBC164848 035 $a(OCoLC)85820317 035 $a(EXLCZ)991000000000377325 100 $a20030414d2003 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aPsychopharmacology$b[electronic resource] $ean introduction /$fRene? Spiegel ; with contributions by S. Hossein Fatemi ... [et al.] 205 $a4th ed. 210 $aChichester, West Sussex, England ;$aHoboken, NJ $cJohn Wiley & Sons$dc2003 215 $a1 online resource (424 p.) 300 $aDescription based upon print version of record. 311 $a0-471-56039-1 311 $a0-470-84691-7 320 $aIncludes bibliographical references (p. [331]-371) and index. 327 $aPsychopharmacology; Contents; Preface; Preface to Third Edition; Preface to Second Edition; Foreword (by Herbert Meltzer); 1 Modern Psychopharmaceuticals (Revision by Hossein Fatemi); 1.1 Definition and classification; 1.2 Antipsychotics; 1.2.1 Clinical actions and uses; 1.2.2 The best-known products; 1.2.3 Differences between different products; 1.2.4 Side effects ('adverse effects') of antipsychotics; 1.2.5 Neuroleptics and tardive dyskinesias: unanswered questions; 1.3 Antidepressants; 1.3.1 Clinical actions and uses; 1.3.2 The best-known products; 1.3.3 How effective are antidepressants? 327 $a1.3.4 Side effects of antidepressants1.4 Mood stabilizers; 1.4.1 Clinical actions and uses; 1.4.2 Side effects of mood stabilizers; 1.5 Anxiolytics and hypnotics; 1.5.1 Clinical actions and uses; 1.5.2 The best-known products; 1.5.3 Anxiolytics or psychotherapy?; 1.5.4 Side effects of anxiolytics; 1.5.5 Dependency on benzodiazepines; 1.5.6 Alternatives to benzodiazepines; 1.6 Psychostimulants; 1.6.1 Actions and uses of psychostimulants; 1.6.2 The best-known psychostimulants; 1.7 Nootropics and antidementia drugs; 1.8 Concluding comment; 2 The History of Psychopharmacology; 2.1 Introduction 327 $a2.2 Psychopharmacology in the ancient world and Middle Ages2.2.1 The most important substances; 2.2.2 Psychopharmaceuticals and the history of psychiatry; 2.3 The modern age: psychopharmacology before chlorpromazine; 2.4 The discovery of modern psychopharmaceuticals; 2.4.1 Chlorpromazine; 2.4.2 Antidepressants; 2.4.3 Tranquillizers; 2.5 Discussion: how were modern psychopharmaceuticals discovered?; 2.5.1 Chance discovery; 2.5.2 Serendipity and spirit of the age (Zeitgeist); 2.5.3 Quantitative aspects; 2.6 The past 20 years; 2.6.1 Atypical antipsychotic drugs; 2.6.2 New antidepressants: SSRIs 327 $a2.6.3 Drugs to treat Alzheimer's disease (AD)2.7 Concluding remarks; 3 Effects of Psychotropic Medication on Healthy Subjects; 3.1 Introduction; 3.2 Studies conducted by Emil Kraepelin; 3.3 Assessment methods used in drug experiments on healthy volunteers; 3.3.1 Methods for recording subjective drug effects; 3.3.2 Methods for recording behavioral drug effects; 3.3.3 Neurophysiological parameters; 3.4 Findings in drug experiments on healthy volunteers; 3.4.1 Antipsychotic drugs; 3.4.2 Antidepressant drugs; 3.4.3 Anxiolytic and hypnotic drugs; 3.4.4 Psychostimulant drugs 327 $a3.4.5 Nootropics and antidementia drugs3.5 Discussion; 3.5.1 Differential drug effects; 3.5.2 Sensitivity of the assessment methods used in pharmacopsychology; 3.5.3 Understanding and predicting clinical drug effects; 3.5.4 Theory-orientated issues; 3.6 Conclusions; 4 Preclinical Research in Psychopharmacology (by Conrad Gentsch); 4.1 Introduction; 4.2 The target; 4.2.1 The nervous system; 4.2.2 Neurons; 4.2.3 Synapses; 4.2.4 Receptors; 4.2.5 Ligands; 4.2.6 Interaction between the ligand and receptor; 4.2.7 Neurotransmitters 327 $a4.3 Hypotheses relating to the mode of action of psychopharmaceuticals 330 $aDescribes the latest advances in psychopharmacology - one of the most rapidly developing fields in modern science. This latest edition has been updated to cover new developments in drug therapy and research including newly introduced antipsychotics, antidepressants and antidementia drugs. Sections on the treatment of depression and dementia have been revised to include new developments in treatment strategies. It will be welcomed for its essentially clinical and psychological approach to modern pharmaceuticals, their therapeutic uses and limitations, adverse reactions and future directions for 606 $aPsychopharmacology 615 0$aPsychopharmacology. 676 $a615.78 676 $a615/.78 700 $aSpiegel$b Rene?$01675026 701 $aFatemi$b S. Hossein$01675027 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830009303321 996 $aPsychopharmacology$94040216 997 $aUNINA